VE-822
| CAS No. | 1232416-25-9 | Cat. No. | BCP07948 |
| Name | VE-822 | ||
| Synonyms | VE822; VE 822; VX970; VX-970; VX 970; Berzosertib; | ||
| Formula | C24H25N5O3S | M. Wt | 463.55 |
| Description | VE-822, also known as VX-970 or Berzosertib, is an potent ATR inhibitor. VE-822 inhibited ATR in vitro and in vivo. VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells. VE-822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine. VE-822 markedly prolonged growth delay of pancreatic cancer xenografts after XRT and gemcitabine-based chemoradiation without augmenting normal cell or tissue toxicity. These findings support ATR inhibition as a promising new approach to improve the therapeutic ration of radiochemotherapy for patients with PDAC. | ||
| Pathways | Cell Cycle/DNA Damage PI3K/Akt/mTOR | ||
| Targets | ATM/ATR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.